These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26774359)

  • 41. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC; Otto C; Parhofer KG
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholesterol in the year 2000.
    Vance DE; Van den Bosch H
    Biochim Biophys Acta; 2000 Dec; 1529(1-3):1-8. PubMed ID: 11111073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Treatment of Disorders of Lipid Metabolism.
    Parhofer KG
    Dtsch Arztebl Int; 2016 Apr; 113(15):261-8. PubMed ID: 27151464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances In reverse Cholesterol Transport.
    Wang HH; Garruti G; Liu M; Portincasa P; Wang DQ
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s27-s42. PubMed ID: 29080338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hypercholesterolemia - Where are we today? Where are we going?].
    Gitt AK; Zahn R
    Herz; 2016 Aug; 41(5):413-20. PubMed ID: 27412663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
    Neumann CL; Schettler E; Schettler VJ
    Blood Purif; 2016; 41(4):270-6. PubMed ID: 26789774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A mathematical model of atherosclerosis with reverse cholesterol transport and associated risk factors.
    Friedman A; Hao W
    Bull Math Biol; 2015 May; 77(5):758-81. PubMed ID: 25205457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Morphological aspects of atherosclerosis lesion: past and present].
    Gaudio E; Carpino G; Grassi M; Musca A
    Clin Ter; 2006; 157(2):135-42. PubMed ID: 16817503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [HDL-cholesterol--active or passive participant in the pathogenesis of atherosclerosis? (II)].
    Artenie A; Artenie R; Ungureanu D; Botnariu G; Anisies E; Ionescu SD; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(3):503-8. PubMed ID: 15832963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Two thousand years of historical study on the words atheroma, atheromatosis, atherosclerosis, arteriosclerosis].
    Cottet J; Lenoir M
    Bull Acad Natl Med; 1992 Dec; 176(9):1385-90; discussion 1390-1. PubMed ID: 1303293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nikolai N. Anitschkow and the lipid hypothesis of atherosclerosis.
    Buja LM
    Cardiovasc Pathol; 2014; 23(3):183-4. PubMed ID: 24484612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
    Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins and peripheral arterial disease.
    Markel A
    Int Angiol; 2015 Oct; 34(5):416-27. PubMed ID: 25410295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.